glp-1 adoption consumer trends: PwC New Demand in an Old

Furthermore, Jensterle et al.in another study demonstrated that liraglutide 3.0 mg/day was more effective in reducing BMI and WC in PCOS patients with obesity than the combination of metformin 1000 mg BID + liraglutide at low doses (1.2 mg/day), that has hitherto been considered one of the more promising treatment [63]

Implications for telehealth companies: With brand-name GLP-1 prices dropping , telehealth players in the weight loss drug space need a new strategy to attract and retain members

The ideal scenario is losing fat while keeping or even building muscle

Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases (JAMA Internal Medicine)

Y., Preda, T., & Lord, R